ImmunoPrecise Antibodies Ltd.

(TSXV:IPA) (OTC:IPATF)

ImmunoPrecise Antibodies provides its customers with custom antibody engineering and production services to support their research and development efforts.  The target markets for the company's antibody and peptide products includes organizations in the academic, biological, diagnostics and pharmaceutical fields. ImmunoPrecise operates from state of the art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia.  The company employs an experienced group of R&D scientists, and over the last 25 years its investments in research have led to the creation of innovative and proprietary technologies and methods that significantly improve the speed and efficiency of monoclonal and polyclonal antibody production.

ImmunoPrecise Antibodies Ltd.
CF engaged for IPO at
$0.30 in Dec 2016

Corporate Videos and Other Information

ImmunoPrecise to Acquire U-Protein and Announces $4,000,000 Financing

VIEW ALL -

TOP